Alphagan P : HCP - Coexisting Disorders


	Many of your patients may have coexisting systemic disorders¹ Treating glaucoma patients is complicated by the following medical conditions¹:

ALPHAGAN^® P ophthalmic solution is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information
ALPHAGAN^® P (brimonidine tartrate ophthalmic solution) 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Although ALPHAGAN^® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN^® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus.

Please click here for full Prescribing Information.

^{1. Gottfredsdottir MS, Allingham RR, Shields MB. Physicians' guide to interactions between glaucoma and systemic medications. J Glaucoma. 1997;6(6):377-383.}